This company listing is no longer active
Calliditas Therapeutics Future Growth
Future criteria checks 5/6
Calliditas Therapeutics is forecast to grow earnings and revenue by 55.5% and 34.3% per annum respectively.
Key information
55.5%
Earnings growth rate
n/a
EPS growth rate
| Pharmaceuticals earnings growth | 21.6% |
| Revenue growth rate | 34.3% |
| Future return on equity | n/a |
| Analyst coverage | Good |
| Last updated | 11 Oct 2024 |
Recent future growth updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 4,963 | 1,451 | 4,590 | 4,617 | 4 |
| 12/31/2025 | 3,274 | 836 | 1,703 | 1,735 | 6 |
| 12/31/2024 | 2,021 | -68 | 358 | 374 | 6 |
| 6/30/2024 | 1,601 | -480 | -258 | -245 | N/A |
| 3/31/2024 | 1,311 | -525 | -414 | -401 | N/A |
| 12/31/2023 | 1,207 | -466 | -447 | -435 | N/A |
| 9/30/2023 | 1,184 | -451 | -230 | -227 | N/A |
| 6/30/2023 | 1,150 | -292 | -292 | -290 | N/A |
| 3/31/2023 | 944 | -393 | -354 | -352 | N/A |
| 12/31/2022 | 803 | -412 | -314 | -311 | N/A |
| 9/30/2022 | 405 | -628 | -724 | -703 | N/A |
| 6/30/2022 | 343 | -608 | -634 | -611 | N/A |
| 3/31/2022 | 279 | -576 | -541 | -519 | N/A |
| 12/31/2021 | 229 | -500 | -484 | -462 | N/A |
| 9/30/2021 | 199 | -452 | -422 | -420 | N/A |
| 6/30/2021 | 0 | -600 | -490 | -490 | N/A |
| 3/31/2021 | 0 | -501 | -425 | -425 | N/A |
| 12/31/2020 | 1 | -433 | -309 | -309 | N/A |
| 9/30/2020 | 47 | -286 | -233 | -235 | N/A |
| 6/30/2020 | 47 | -198 | -64 | -48 | N/A |
| 3/31/2020 | 185 | -54 | -57 | -40 | N/A |
| 12/31/2019 | 185 | -33 | -87 | -71 | N/A |
| 9/30/2019 | 138 | -54 | -86 | -68 | N/A |
| 6/30/2019 | 138 | -35 | -166 | -166 | N/A |
| 3/31/2019 | N/A | -136 | -144 | -144 | N/A |
| 12/31/2018 | N/A | -132 | -128 | -128 | N/A |
| 9/30/2018 | N/A | -128 | -112 | -112 | N/A |
| 6/30/2018 | N/A | -115 | -114 | -114 | N/A |
| 3/31/2018 | N/A | -113 | N/A | -89 | N/A |
| 12/31/2017 | N/A | -87 | N/A | -68 | N/A |
| 12/31/2016 | N/A | -57 | N/A | -55 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LC8A is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.8%).
Earnings vs Market: LC8A is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: LC8A is expected to become profitable in the next 3 years.
Revenue vs Market: LC8A's revenue (34.3% per year) is forecast to grow faster than the German market (5.5% per year).
High Growth Revenue: LC8A's revenue (34.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if LC8A's Return on Equity is forecast to be high in 3 years time